Latest Articles

Publication Date
Immune escape in endometriosis: mechanisms, reprogramming strategies, and precision interventions.

Endometriosis is a prevalent estrogen-dependent inflammatory disorder that compromises women's quality of life and fertility through chronic pelvic pain, inflammation, and reproductive dysfunction. Current clinical management remains largely palliative, with …

Published: July 10, 2026, midnight
Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.

Postoperative recurrence remains a major obstacle to durable remission in patients with solid tumors, even after complete macroscopic resection. Growing evidence suggests that surgery creates a transient yet highly permissive …

Published: July 3, 2026, midnight
Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? - ESMO Daily Reporter

Immunotherapy in dMMR/MSI-H endometrial cancer – a true game-changer? ESMO Daily Reporter

Published: June 18, 2026, 2:24 p.m.
Deciphering immune-inflammatory dysregulation in the endometriotic microenvironment: insights from single-cell omics and artificial intelligence.

Endometriosis is a prevalent chronic inflammatory gynecological disorder affecting approximately 10% of reproductive-age women worldwide, characterized by endometrial-like tissue outside the uterine cavity. Ectopic lesion growth tracks closely with immune-inflammatory …

Published: June 11, 2026, midnight
The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years - MSN

The RUBY trial: For certain patients, immunotherapy-chemo combination keeps advanced endometrial cancer from progressing for years MSN

Published: June 8, 2026, 8:37 p.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - MSN

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer MSN

Published: June 2, 2026, 12:41 a.m.
Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer - Medical Xpress

Addition of immunotherapy shows survival benefit in follow-up trial for primary advanced or recurrent endometrial cancer Medical Xpress

Published: June 1, 2026, 8 p.m.
Immunotherapy Addition Demonstrates Sustained Survival Benefits in - Bioengineer.org

Immunotherapy Addition Demonstrates Sustained Survival Benefits in Bioengineer.org

Published: May 29, 2026, 11:56 p.m.
Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations - CancerNetwork

Potential Immunotherapy After Immunotherapy in Select Endometrial Cancer Populations CancerNetwork

Published: May 25, 2026, 1:56 p.m.
Endometriosis and ovarian cancer risk.

To critically evaluate the evidence linking endometriosis to ovarian cancer, with particular focus on endometrioid and clear cell histologic subtypes, and to inform risk stratification and patient counseling.

Published: May 12, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!